Psyence Biomedical (NASDAQ:PBM) Shares Cross Below 200 Day Moving Average – Should You Sell?

Psyence Biomedical Ltd. (NASDAQ:PBM)’s stock price passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $4.01 and traded as low as $3.63. Psyence Biomedical shares last traded at $3.66, with a volume of 45,711 shares changing hands.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Wall Street Zen upgraded shares of Psyence Biomedical to a “hold” rating in a report on Saturday, October 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Psyence Biomedical in a report on Thursday, October 15th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company currently has an average rating of “Sell”.

Psyence Biomedical Stock Performance

The stock has a 50-day simple moving average of $4.88 and a 200 day simple moving average of $4.01. The company has a market cap of $8.39 million, a P/E ratio of 0.14 and a beta of 1.68.

Psyence Biomedical Company Profile

Psyence Biomedical, Inc is a clinical-stage biotechnology company developing psychedelic-based therapeutics for mental health conditions. The company focuses on naturally derived psilocybin treatments intended to address psychological and emotional distress associated with serious or life-altering illnesses.

Its lead development program, Psyence-1, is being evaluated as a potential treatment for adjustment disorder in patients facing life-threatening illnesses, including cancer. The program is designed to combine psilocybin administration with psychological support and is being advanced through clinical research and development activities.

Psyence Biomedical was formed as part of the Psyence Group and became a publicly traded company following a business combination with Newcourt Acquisition Corp.